Tilray Brands (TLRY) Non-Current Debt (2020 - 2026)
Tilray Brands (TLRY) posted Non-Current Debt of $135.0 million for Q1 2026, down 2.71% on a QoQ basis from $138.7 million in Q4 2025.
Tilray Brands (TLRY) Non-Current Debt (2020 - 2026) Analysis & Trends
Tilray Brands' Non-Current Debt history runs 7 years deep, the most recent figure standing at $135.0 million for Q1 2026.
- Quarterly Non-Current Debt changed N/A year-over-year to $135.0 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $135.0 million (changed N/A YoY) and the FY2025 annual result came in at $148.5 million, down 6.23% from the prior year.
- Non-Current Debt was $135.0 million for Q1 2026 at Tilray Brands, down from $138.7 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $169.1 million in Q4 2023 and bottomed at $89.4 million in Q1 2023.
- A 5-year average of $140.5 million and a median of $146.3 million in 2025 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2022 — Non-Current Debt plunged 30.69% — and 2024, when it surged 85.25%.
- Tilray Brands' Non-Current Debt stood at $152.2 million in 2022, then increased by 11.14% to $169.1 million in 2023, then slipped by 11.96% to $148.9 million in 2024, then fell by 6.81% to $138.7 million in 2025, then declined by 2.71% to $135.0 million in 2026.
- Business Quant data shows TLRY's Non-Current Debt at $135.0 million in Q1 2026, $138.7 million in Q4 2025, and $144.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Tilray Brands | 465.02 Mn | 373.06 Mn | 54.95 Mn | 134.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 134.98 Mn |
| Nov 30, 2025 | 138.74 Mn |
| Aug 31, 2025 | 144.18 Mn |
| May 31, 2025 | 148.49 Mn |
| Nov 30, 2024 | 148.87 Mn |
| Aug 31, 2024 | 155.27 Mn |
| May 31, 2024 | 158.35 Mn |
| Feb 29, 2024 | 165.65 Mn |
| Nov 30, 2023 | 169.10 Mn |
| Aug 31, 2023 | 152.39 Mn |
| May 31, 2023 | 136.89 Mn |
| Feb 28, 2023 | 89.42 Mn |
| Nov 30, 2022 | 152.15 Mn |
| Aug 31, 2022 | 114.29 Mn |
| May 31, 2022 | 117.88 Mn |
| Feb 28, 2022 | 121.21 Mn |
| Nov 30, 2021 | 151.82 Mn |
| Aug 31, 2021 | 164.91 Mn |
| May 31, 2021 | 167.49 Mn |
| May 31, 2020 | 94.03 Mn |